Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Stephens reissued their overweight rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock.

Several other research analysts have also weighed in on ATNM. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. Maxim Group dropped their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Stock Up 5.8 %

ATNM opened at $1.47 on Tuesday. The company has a market cap of $45.86 million, a PE ratio of -1.06 and a beta of 0.14. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24. The company has a fifty day moving average of $1.76.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ATNM. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the second quarter worth about $92,000. Renaissance Technologies LLC acquired a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter worth approximately $142,000. Interchange Capital Partners LLC bought a new stake in Actinium Pharmaceuticals during the third quarter worth $37,000. Rhumbline Advisers lifted its stake in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares during the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).